Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

Propylthiouracil, a thyroid medication, can cause skin blood clots and immune-related blood vessel inflammation.

Adalimumab may cause severe hair loss in some patients.

Patients with Alopecia Areata have higher levels of certain inflammatory markers.

Inflammation damages sweat ducts, causing sweat gland injury.

People with alopecia areata have higher levels of a heart disease marker than those without hair loss.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.

A new diagnostic model can help better diagnose and understand Alopecia Areata.

High CRP levels could indicate vitamin D deficiency in people with alopecia areata.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

Abatacept may help some people with alopecia areata regrow hair.

Alopecia areata may be linked to higher heart disease risk.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

A man had bad reactions to a hair loss treatment called DNCB.

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

People with alopecia areata often have thyroid autoimmunity.

An 87-year-old woman was diagnosed with type 3 autoimmune polyendocrine syndrome and had multiple autoimmune issues.